These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11144651)
1. Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer. Matsuyama H; Baba Y; Yamakawa G; Yamamoto N; Naito K Int J Urol; 2000 Nov; 7(11):409-14. PubMed ID: 11144651 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria. Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203 [TBL] [Abstract][Full Text] [Related]
4. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613 [TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters. Egawa S; Suyama K; Takashima R; Mizoguchi H; Kuwao S; Baba S Int J Urol; 1999 Oct; 6(10):493-501. PubMed ID: 10533900 [TBL] [Abstract][Full Text] [Related]
7. [Usefulness of free/total PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from prostatic cancer]. Mosquera Madera J; Pinto Sierra I; Enguix Armada A; Sahagún Argüello JL Actas Urol Esp; 2001 Oct; 25(9):651-5. PubMed ID: 11765549 [TBL] [Abstract][Full Text] [Related]
8. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484 [TBL] [Abstract][Full Text] [Related]
9. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448 [TBL] [Abstract][Full Text] [Related]
10. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703 [TBL] [Abstract][Full Text] [Related]
11. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444 [TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen. Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060 [TBL] [Abstract][Full Text] [Related]
13. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men. Akduman B; Alkibay T; Tuncel A; Bozkirli I Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873 [TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. Khosravi J; Diamandi A; Mistry J; Scorilas A J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033 [TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen density of the transition zone for early detection of prostate cancer. Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889 [TBL] [Abstract][Full Text] [Related]